Business Description
Bausch & Lomb Corp
NAICS : 333314
SIC : 3912
ISIN : CA0717051076
Description
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | 9.12 | |||||
| Interest Coverage | 0.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.89 | |||||
| Beneish M-Score | -2.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | -10.7 | |||||
| 3-Year EPS without NRI Growth Rate | -89.2 | |||||
| 3-Year Book Growth Rate | -10.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 1.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.46 | |||||
| 9-Day RSI | 27.07 | |||||
| 14-Day RSI | 33.24 | |||||
| 6-1 Month Momentum % | -10.13 | |||||
| 12-1 Month Momentum % | -2.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.21 | |||||
| Days Inventory | 169.47 | |||||
| Days Sales Outstanding | 67.92 | |||||
| Days Payable | 88.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -23.49 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.4 | |||||
| Operating Margin % | 4.9 | |||||
| Net Margin % | -6.3 | |||||
| FCF Margin % | -4.76 | |||||
| ROE % | -3.76 | |||||
| ROA % | -2.17 | |||||
| ROIC % | 2.79 | |||||
| ROC (Joel Greenblatt) % | 5.85 | |||||
| ROCE % | 1.09 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 78.74 | |||||
| PS Ratio | 1.25 | |||||
| PB Ratio | 0.76 | |||||
| EV-to-EBIT | 81.73 | |||||
| EV-to-Forward-EBIT | 47.09 | |||||
| EV-to-EBITDA | 19.08 | |||||
| EV-to-Forward-EBITDA | 14.92 | |||||
| EV-to-Revenue | 2.29 | |||||
| EV-to-Forward-Revenue | 1.45 | |||||
| EV-to-FCF | -47.96 | |||||
| Earnings Yield (Greenblatt) % | 1.22 | |||||
| FCF Yield % | -3.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bausch & Lomb Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,844.059 | ||
| EPS (TTM) (€) | -0.689 | ||
| Beta | 0 | ||
| Volatility % | 30.67 | ||
| 14-Day RSI | 33.24 | ||
| 14-Day ATR (€) | 0.329729 | ||
| 20-Day SMA (€) | 14.47 | ||
| 12-1 Month Momentum % | -2.07 | ||
| 52-Week Range (€) | 12.5 - 18.6 | ||
| Shares Outstanding (Mil) | 350.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bausch & Lomb Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bausch & Lomb Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bausch & Lomb Corp Frequently Asked Questions
What is Bausch & Lomb Corp(FRA:S2L)'s stock price today?
The current price of FRA:S2L is €13.20. The 52 week high of FRA:S2L is €18.60 and 52 week low is €12.50.
When is next earnings date of Bausch & Lomb Corp(FRA:S2L)?
The next earnings date of Bausch & Lomb Corp(FRA:S2L) is 2024-05-01.
Does Bausch & Lomb Corp(FRA:S2L) pay dividends? If so, how much?
Bausch & Lomb Corp(FRA:S2L) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers